Evidence map›Paper›PMID 35320520›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Alkylation of Galectin-1 with Iodoacetamide and Mass Spectrometric Mapping of the Sites of Incorporation.

Shang-Chuen Wu, Anu Paul, Richard D Cummings, Christa L Feasley, Connie M Arthur, Sean R Stowell

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shang-Chuen Wu *Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anu Paul *Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Richard D CummingsHarvard Glycomics Center, Harvard Medical School, Boston, MA, USA.
Christa L FeasleyCytovance Technologies, Oklahoma City, OK, USA.
Connie M ArthurJoint Program in Transfusion Medicine, Brigham and Women's Hospital, National Center for Functional Glycomics, Harvard Medical School, Boston, MA, USA. cmarthur@bwh.harvard.edu.
Sean R StowellHarvard Glycomics Center, Harvard Medical School, Boston, MA, USA. srstowell@bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

Examining the Mechanisms of RBC Alloimmunization HyperrespondersR01HL154034 · NHLBI · EMORY UNIVERSITY · PI ARTHUR, CONNIE M · 2020 to 2024
$2.1M
Integrating microbial glycan arrays with genomic sequences to study host microbe interactionsU01CA242109 · NCI · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D, STOWELL, SEAN R · 2019 to 2021
$1.5M
NCI NIH HHS U01 CA242109NHLBI NIH HHS R01 HL154034
6 · The paper itself

Abstract

Galectins can display unique sensitivity to oxidative changes that result in significant conformational alterations that prevent carbohydrate recognition. While a variety of approaches can be utilized to prevent galectin oxidation, several of these require inclusion of reducing agents that not only prevent galectins from undergoing oxidative inactivation but can also interfere with normal redox potentials required for fundamental cellular processes. To overcome the limitations associated with placing cells in an artificial reducing environment, cysteine residues on galectins can be directly alkylated with iodoacetamide to form a stable thioether adduct that is resistant to further modification. Iodoacetamide alkylated galectin remains stable over prolonged periods of time and retains the carbohydrate binding and biological activities of the protein. As a result, this approach allows examination of the biological roles of a stabilized form of galectin-1 without introducing the confounding variables that can occur when typical soluble reducing agents are employed.

Indexed as

Galectin 1GalectinsAlkylationIodoacetamideMass SpectrometryGalectin 1GalectinsIodoacetamideAlkylationGalectin-1Mass spectrometryOxidationReducing agents

Identifiers

PMID35320520
OpenAlexW4221000449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.